Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis
Asha Therapeutics to Present at AD/PDâ„¢ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year
Asha Therapeutics Selected as a BLUE KNIGHTâ„¢ Company by Johnson & Johnson Innovation and BARDA
Inside the Innovation Arena – A Recap of Our BLUE KNIGHT™ QuickPitch: Activating for the Future
Asha TX to present breakthrough data for ASHA-044 tareting Beta-Catenin in colorectal cancer at NGIO
Targeting mitochondria in ME/CFS and Long Haul COVID with ASHA-091
Asha Therapeutics Announces the Presentation of New Data on ASHA-1007, a Novel VHL Recruiter for TPD
Asha Therapeutics CSO, Dr. Bradlee Heckmann speaking at AD/PD 2023
Asha Therapeutics Announces the Appointment of Dr. Craig Blackstone to its Board of Directors
Asha Therapeutics Appoints Kirsten Flowers to its Board of Directors
Dr. Craig Blackstone, M.D., Ph.D., appointed as Chair, Asha Therapeutics’ Scientific Advisory Board
Asha Therapeutics presents at 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
ASHA-091 demonstrates efficacy in Parkinson’s Disease